The current stock price of HYPD is 3.04 USD. In the past month the price decreased by -18.93%.
ChartMill assigns a fundamental rating of 2 / 10 to HYPD. Both the profitability and financial health of HYPD have multiple concerns.
Over the last trailing twelve months HYPD reported a non-GAAP Earnings per Share(EPS) of -50.93. The EPS increased by 4.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.17% | ||
| ROE | -70.41% | ||
| Debt/Equity | 0.11 |
8 analysts have analysed HYPD and the average price target is 5.99 USD. This implies a price increase of 97.12% is expected in the next year compared to the current price of 3.04.
For the next year, analysts expect an EPS growth of 33.51% and a revenue growth -7.67% for HYPD
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
HYPERION DEFI INC
295 Madison Avenue, Suite 2400
New York City NEW YORK US
Employees: 13
Phone: 18333936684
Hyperion DeFi, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The firm is focused on providing simplified access to the Hyperliquid ecosystem. The company is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. The company has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.
The current stock price of HYPD is 3.04 USD. The price increased by 4.11% in the last trading session.
HYPD does not pay a dividend.
HYPD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HYPD.
HYPERION DEFI INC (HYPD) has a market capitalization of 24.62M USD. This makes HYPD a Nano Cap stock.
You can find the ownership structure of HYPERION DEFI INC (HYPD) on the Ownership tab.